Phibro Animal Health (PAHC) EBITDA Margin (2012 - 2026)

Phibro Animal Health's EBITDA Margin history runs 15 years deep, the most recent figure standing at 11.64% for Q1 2026.

• On a quarterly basis, EBITDA Margin rose 201.0% year-over-year to 11.64% in Q1 2026; TTM through Mar 2026 was 12.0%, a 400.0% increase from a year earlier, with the FY2025 full-year figure at 8.52%, up 328.0% from the prior year.
• EBITDA Margin slipped to 11.64% in Q1 2026 per PAHC's latest filing, from 13.46% in the prior quarter.
• Across five years, EBITDA Margin topped out at 14.09% in Q3 2025 and bottomed at 0.31% in Q3 2023.
• The 5-year median for EBITDA Margin is 8.01% (2022), against an average of 8.19%.
• Across the five-year window, EBITDA Margin sank 620 bps in 2023 and jumped 729 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 6.48% in 2022, then declined by 3 bps to 6.28% in 2023, then soared by 31 bps to 8.26% in 2024, then soared by 63 bps to 13.46% in 2025, then fell by 14 bps to 11.64% in 2026.
• Per Business Quant, the three latest PAHC EBITDA Margin figures stand at 11.64% (Q1 2026), 13.46% (Q4 2025), and 14.09% (Q3 2025).